April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. BRAMD
Author Affiliations & Notes
  • Ann-Sofie Marie Evelyn Schauwvlieghe
    Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
  • Greetje Dijkman
    Ophthalmology, Leiden University Medical Centre, Leiden, Netherlands
  • Johanna M M Hooymans
    Ophthalmology, University Medical Center Groningen, Groningen, Netherlands
  • Frank D Verbraak
    Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
  • Marcel G Dijkgraaf
    Clinical Research Unit, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
  • Tunde Peto
    The NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology,, London, United Kingdom
  • Johannes R Vingerling
    Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
    Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands
  • Carel Hoyng
    Ophthalmology, Radboud University Medical Centre, Nijmegen, Netherlands
  • Reinier O Schlingemann
    Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    Netherlands Institute for Neurosciences, Amsterdam, Netherlands
  • Footnotes
    Commercial Relationships Ann-Sofie Schauwvlieghe, None; Greetje Dijkman, Bayer (C), Novartis (C); Johanna Hooymans, None; Frank Verbraak, Dutch advisory board Novartis & Bayer (S); Marcel Dijkgraaf, None; Tunde Peto, None; Johannes Vingerling, None; Carel Hoyng, None; Reinier Schlingemann, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 870. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ann-Sofie Marie Evelyn Schauwvlieghe, Greetje Dijkman, Johanna M M Hooymans, Frank D Verbraak, Marcel G Dijkgraaf, Tunde Peto, Johannes R Vingerling, Carel Hoyng, Reinier O Schlingemann, ; Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. BRAMD. Invest. Ophthalmol. Vis. Sci. 2014;55(13):870.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the effectiveness of bevacizumab and ranibizumab in the treatment of exudative age-related macular degeneration (AMD). In patients ≥ 60 years of age with primary or recurrent sub- or juxtafoveal choroidal neovascularization (CNV) secondary to AMD with a total area of CNV < 12 disc areas and a best corrected visual acuity (BCVA) score between 20 and 78 letters on an EDTRS like chart in the study eye.

Methods: In this double-masked clinical trial 327 patients were randomized to 1.25 mg bevacizumab or 0.5 mg ranibizumab given as monthly intravitreal injections during one year. Intention to treat with last observation carried forward analysis was performed. Primary outcome was the change in BCVA in the study eye from baseline to 12 months. The non-inferiority margin was set at 4 letters. Secondary outcomes were the proportions of patients with a gain or loss ≥ 15 letters or more, a BCVA ≥ 20/40 or more at 12 months, the change in central area retinal thickness (CRT) by optical coherence tomography (OCT) at 4 and 12 months and the number of adverse events in 12 months.

Results: Bevacizumab (n=161) was not inferior to ranibizumab (n=166). The mean gain in BCVA was 5.1 (±14.1) letters in the bevacizumab group and 6.4 (±12.2) letters in the ranibizumab group (p= 0.37). The lower limit of the 95% confidence interval of the difference in BCVA gain between the two groups was 3.72. The response to bevacizumab was more varied than in the ranibizumab group, with 24% of patients showing a gain of ≥15 letters, 11% a loss of ≥15 letters and 65% a gain or loss < 15 letters in the bevacizumab group compared to 19%, 5% and 76% respectively in the ranibizumab group (p=0.038). No significant differences in absolute CRT and CRT change at 12 months (p=0.13) were observed, but any sub- or intraretinal fluid on OCT was observed more frequently in the bevacizumab group (45% vs 31 %, p=0.020). The occurrence of serious adverse events and adverse events was similar in the two groups, with 34 SAEs and 256 AEs in the bevacizumab group and 37 SAEs and 299 AEs in the ranibizumab group (p= 0.87 and p=0.48, respectively).

Conclusions: The efficacy of bevacizumab was not inferior to ranibizumab. The response to bevacizumab was more varied with higher percentages of both gainers and losers and more frequently observed retinal fluid on OCT at 12 months when compared to the ranibizumab group.

Keywords: 412 age-related macular degeneration • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×